Tag: Infectious Disease

PharmaSignal — Infectious Disease therapeutic area

Moderna, after losing US funding, rebounds to start mRNA bird flu vaccine trial

BioPharma Dive

A program that got caught up in HHS decision to abandon mRNA research was revived by a public-private coalition and is now beginning a large, late-stage test that could support a future approval.

Clinical DataRead full story

Pivotal trial of Moderna’s H5N1 bird flu jab gets underway

Pharmaphorum

The first volunteers in a large-scale trial of Moderna’s mRNA-based vaccine against bird flu have received shots in the UK and US.

Clinical DataRead full story

MSD secures EC approval for Enflonsia to prevent infant RSV infection

Pharmaceutical Business Review

This approval authorises Enflonsia’s marketing across all 27 European Union member states, Iceland, Liechtenstein and Norway.

RegulatoryRead full story

Scientists issue call to arms over antifungal resistance

Pharmaphorum

Infectious disease experts from around the world are calling for concerted action to combat a “silent surge” in resistance to antifungal drugs.

Policy / PricingRead full story

Shionogi secures $482m BARDA contract to tackle AMR crisis

Pharmaceutical Technology

Shionogi will use the money from BARDA to build an American antibiotic manufacturing site as the US looks to fight antimicrobial resistance.

M&A / DealsRead full story

EU invests 30m to fight antimicrobial resistance

Pharmaphorum

The EU has pledged 30m in funding for countermeasures to antimicrobial resistance, earmarked for the discovery and development of new antibacterials.

Policy / PricingRead full story

Pfizer, BioNTech Halt Large US COVID-19 Vaccine Trial Over Slow Enrollment

BioSpace

COVID-19 partners Pfizer and BioNTech have been unable to recruit healthy adults aged 50 to 64 fast enough to deliver relevant post-marketing data.

Clinical DataRead full story

Pfizer, Valneva to seek approval of Lyme disease vaccine despite mixed study results

BioPharma Dive

The partners said the shot produced clinically meaningful efficacy despite missing its main study objective, a finding they blamed on a lower-than-expected rate of infections during the trial.

RegulatoryRead full story